Influenza is the only remaining major epidemic viral disease. Immunization is often performed, although the protective effect reported in different studies varies considerably [1] [2] [3] . Current recommendations advise annual vaccination of certain groups in the population considered to be at high risk [4] .
Patients with Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes of long duration may be predisposed to viral as well as bacterial infections [5] [6] [7] . Poor metabolic control has been suggested as the cause of several abnormalities in the immune response including impaired phagocytosis [8] , increased circulating immune complexes [9] , reduced lymphocyte transformation [10] and decreased percentage of T cells [11] . In view of these findings, some patients may be considered as having secondary immunodeficiency [12] .
Infectious diseases, and in particular influenza, are a common cause of clinical instability in patients with diabetes and may precipitate diabetic ketoacidosis. It is not known whether patients with long standing diabetes develop influenza more frequently than normal subjects as a consequence of an altered immune response.
Therefore, in the present study we have investigated the humoral and cell-mediated immune response of diabetic patients following vaccination with influenza virus.
Subjects and methods

Subjects
Following approval by the Ethical Committee, informed consent was obtained from the diabetic patients and control subjects. The groups were made up as follows: 10patients with Type 1 diabetes (3 females and 7 males, mean age 36 +_ 14, duration of disease of 15 + 12 years); 21 patients Type 2 with diabetes (9 females and 12 males, mean age 54+13, duration of disease of 11 _+ 7 years); 9 normal subjects (14 females and 5 males, mean age 32 _+ 8) as the control group for Type i diabetic patients; 10 normal subjects (5 females and 5 males, mean age 52+ 11) as the control group for Type 2 diabetic patients. Investigations in the patients included evaluation of metabolic control [fasting blood glucose and HbAa using ion exchange chromatography (normal range 4.0-7.0%, Biorad, Milan, Italy)] and routine blood tests (white cell and erythrocyte count, serum creatinin, protein electrophoresis, blood urea nitrogen, serum lipoproteins and liver enzymes). The clinical characteristics of patients studied are shown in Table 1 . The control group was composed of subjects with no family history of diabetes or other autoimmune diseases; they were all in good health at the time of vaccination.
MeNo~
Anti-influenza vaccine was prepared by the Institute Merieux (Lyon, France) and given as a single intramuscular injection (0.5 ml). A trivalent, inactivated prearation was used containing antigens representative of the following strains of influenza viruses recommended for the 1984/85 prophylaxis: A/Chile (H1NI); A/Philippines (H3N2); B/ USSR/100/83. The vaccine contained 15 ug of each haemagglutinin antigen. Blood samples for immunological studies were collected before vaccination and 18 h, 72 h and 1, 2, 3 and 6 weeks. Antibody titres to the 3 virus strains contained in the vaccine were measured using the single radial haemolysis (SRH) technique (13) . The haemolysis was read using a diffusion zone reader (Dynatech) after incubation of plates at 37°C for 3 h. The results are expressed as mean area in mm+SD.
Cell-mediated immunity
The generation of activated lymphocytes was evaluated using two monoclonal antibodies, one of which detects an early activation antigen on lymphocyte surface (4F2) [14] and the other which phenotypes cells with receptors for interleukin-2 (anti-Tac) [15] . B lymphocytes were measured using the L243 monoclonal antibody [16] . Lymphocytes positive for each monoclonal antibody used were evaluated by the indirect immunofluorescence technique. Briefly, 5 x 10 s cells were incubated with 50 ~tl of the relevant monoclonal antibody for 30 rain at 4 °C. Cells were then washed, incubated with IgG goat antimouse fluorescinated antiserum for 30 rain at 4 °C, washed three times and finally placed on a multiwell plate (Hamax, Medicell International, London, UK) for the count of positive cells using an inverted microscope as previously described [17] ,
Statistical analysis
Statistical analysis included Mann-Whitney U test and analysis of variance (repeated measurement design); significance was established as p< 0.05.
Results
Humoral immune response
In normal subjects an antibody response to the virus was obtained which followed the expected pattern [1] [2] [3] . The antibody titre to the different influenza virus strains reached its maximum 1-2 weeks after administration of vaccine in both control subjects and diabetic In patients with Type 2 diabetes, 4 (19%) were nonresponders to all 3 virus strains as opposed to 1 subject in the age-matched control group. When the antibody responses to single B/USSR, A/Philippines and A/ Chile strains were considered, no significant differences were observed with age-matched control subjects (Fig.2) . A normal antibody titre to B/USSR was reached in 67% of patients and control subjects, and to A/Philippines and A/Chile in 72% and 78% respectively. Figure 3 shows the results of activated lymphocytes in patients with Type I diabetes and Type 2 diabetes. The shaded areas represent the values in age-matched control subjects for each group of patients. Overall, a wide variation of the percentage of activated cells was observed in patients and control subjects following vaccination. The only statistically significant difference was the reduction of anti-TAC positive lymphocytes in patients with Type 2 diabetes compared to normal subjects 72 h after vaccination, at the time when the generation of activated cells reaches the peak in normal subjects (p<0.01).
Cell-mediated immune response
No significant changes were observed in the percentage of B lymphocytes except for patients with Type 1 diabetes i week after vaccination. Thus, a significant increase of the percentage of L243 positive cells was found compared to normal subjects (p< 0.02). Glycosylated haemoglobin values were 7.2% +_ 1.7 in patients with Type I diabetes and 6.2% + 1.2 in those with Type 2 diabetes (normal range of the method 4-7%).
Discussion
Overall, the immune response to influenza vaccination in Type 1 and Type 2 diabetic patients does not differ from that observed in age-matched normal subjects, indicating that influenza vaccination may be beneficial in these patients. It should be mentioned that our patients were reasonably controlled at the time of vaccination, and this could have been relevant for the positive response to the virus. However, in the light of previous work suggesting an impaired immune response in poorly controlled patients [18] , we can not exclude the possibility that patients with poor metabolic control might have an attenuated immune response to the virus following vaccination. On the other hand, we would emphasize that patients with Type 1 diabetes showed a prompt and (in the case of A/Chile strain) even higher antibody titre than normal subjects. This has also a counterpart in the cell-mediated immune response as shown by the significant increase in the percentage of B lymphocytes, as compared to normal subjects, 1 week after vaccination at the time when the humoral immune response to the virus is maximal.
The marked immune response observed in patients with Type 1 diabetes, in particular to the A/Chile strain, may be characteristic of these patients. Thus, at the time of diagnosis and even before the onset of clinical symptoms islet cell antibodies, activated T cells [19] and high increased antibody titre to Coxsackie B virus [20] are described in these patients. A genetic predisposition to an exaggerated immune response to exogenous stimuli can then be envisaged. Indirect support for this hypothesis comes from recent data showing that subjects possessing the HLA-DR3 phenotype (both susceptible and non-susceptible to diabetes) show a higher cell-mediated immune response compared to those with other HLA-DR allotypes [21] . Unfortunately, in our study the number of patients with Type 1 diabetes to whom the vaccine was given was too small to correlate the HLA phenotype with the virus antibody titre. The raised immunoreactivity observed in patients with Type 1 diabetes may be also linked to the general phenomenon of the highly specific antibody response for each virus subtype compared to cytotoxic T cells which, once generated, show cross reactivity in their recognition of the different subtypes of influenza virus [22] . The capacity of patients with Type 1 diabetes of generating a higher response to one particular virus subtype could reflect indeed the peculiar immune response of these patients.
A different pattern compared to Type I diabetic patients has been observed in patients with Type 2 diabetes. Overall, we did not find any difference between patients and age-matched control subjects in the humoral immune response to the different virus strains. However, the generation of activated cells, as defined by a monoclonal antibody which phenotypes cells possessing receptors for interleukin-2, was impaired 72 h following the antigenic challenge with the virus. Amongst patients with Type 2 diabetes there were 4 completely anergic (19%); this percentage is higher than expected based on data in the normal population. Thus, several reports indicate that within healthy subjects only 1 out of 10 are non-responders to the vaccine [2, 3] . It is unlikely that metabolic decompensation is implicated in the absence of an immune response in the 4 patients with Type 2 diabetes, as glycosylated haemoglobin levels were raised only in one patient. However, it should be pointed out that despite the lack of a specific immune response -as evaluated by our parameters -these 4 patients did not develop influenza later on.
In conclusion, antigenic challenge with the influenza virus has demonstrated that well controlled diabetic patients have a prompt humoral and cell-mediated immune response to the virus. If patients are well controlled and investigation of lymphocyte subsets does not reveal abnormalities, we would expect these patients to have effective immunization against influenza after vaccination. Indeed, none of our patients developed influenza in the course of the whole following year.
